Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later

Journal of Rheumatology

Volumn 37, Issue 4, 2010, Pages 723-729

  Ichikawa, Yoichi ^a   Saito, Terunobu ^b   Yamanaka, Hisasi ^b   Akizuki, Masashi ^c   Kondo, Hirobumi ^d   Kobayashi, Shigeto ^e   Oshima, Hisaji ^f   Kawai, Shinichi ^a,o   Hama, Nobuaki ^a   Yamada, Hidehiro ^a   Mimori, Tsuneyo ^g,p   Amano, Koichi ^h   Tanaka, Yasushi ⁱ   Matsuoka, Yasuo ^j   Yamamoto, Sumiki ^k   Matsubara, Tsukasa ^l   Murata, Norikazu ^m   Asai, Tomiaki ⁿ   Suzuki, Yasuo ^a,q  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f FUJITA HEALTH UNIVERSITY   (Japan)

^g KEIO UNIVERSITY   (Japan)

^h SAITAMA MEDICAL CENTER   (Japan)

ⁱ Konan Kakogawa Hospital   (Japan)

^j KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^k MATSUYAMA RED CROSS HOSPITAL   (Japan)

^l Matsubara Mayflower Hospital   (Japan)

^m MINAMI OSAKA GENERAL HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^o TOHO UNIVERSITY   (Japan)

^p KYOTO UNIVERSITY   (Japan)

^q TOKAI UNIVERSITY   (Japan)

more..

Author keywords

Disease activity; Disease modifying antirheumatic drugs; Joint erosions; Prognosis; Rheumatoid arthritis

Indexed keywords

BUCILLAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; JOINT DEGENERATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; JOINTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77950656397     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090776     Document Type: Article

References (29)

1. Smolen JS, van der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E, et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-710
2. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-3125 (Pubitemid 44622081)
3. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602
4. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-346 (Pubitemid 34136570)
5. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 2008;59:762-784
6. Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Silman A, et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 1996;313:471-476 (Pubitemid 26280356)
7. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001;44:1736-1743 (Pubitemid 32758218)
8. Guillemin F, Gerard N, van Leeuwen M, Smedstad LM, Kvien TK, van den Heuvel W; EURIDISS Group. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J Rheumatol 2003;30:2585-2589 (Pubitemid 37549334)
9. Goronzy JJ, Matteson EL, Fulbright JW, Warrington KJ, Chang-Miller A, Hunder GG, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004;50:43-54. (Pubitemid 38084286)
10. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B; BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-1095 (Pubitemid 39120360)
11. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008;58:1293-1298
12. Dixey J, Solymossy C, Young A; Early RA Study. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol 2004;31 Suppl 69:48-54. (Pubitemid 38327493)
13. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201. (Pubitemid 40193611)
14. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006;45:478-480
15. Listing J, Rau R, Muller B, Alten R, Gromnica-Ihle E, Hagemann D, Zink A. HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group. J Rheumatol 2000;27:2100-2109
16. Fex E, Jonsson K, Johnson U, Eberhardt K. Development of radiologic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996;35:1106-1115 (Pubitemid 126719646)
17. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-1477 (Pubitemid 30452464)
18. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-2093 (Pubitemid 38924385)
19. Chatham WW, Blackburn WD Jr. Gold and D-penicillamine. In: Coopman WJ, editor. Arthritis and allied conditions. 14th ed. Philadelphia: Lippincott Williams and Wilkins; 2001:717-733
20. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al, and MTX-BUC Combination Study Group. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 2005;15:323-328
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
22. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-1353 (Pubitemid 14231480)
23. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-745
24. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-740 (Pubitemid 23175613)
25. van Riel PL, van Gestel AM, van de Putte LBA. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35 Suppl 2:4-7. (Pubitemid 126719734)
26. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-858
27. Aman S, Paimela L, Leirisalo-Repo M, Risteli J, Kautiainen H, Helve T, et al. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study. J Rheumatol 2000;39:1009-1013
28. Wakitani S, Murata N, Toda Y, Ogawa R, Kaneshige T, Nishimura Y, et al. The relationship between HLA-DRB1 alleles and disease subsets of rheumatoid arthritis in Japanese. Br J Rheumatol 1997;36:630-636 (Pubitemid 27338927)
29. Kochi Y, Yamada R, Kobayashi K, Takahashi A, Suzuki A, Sekine A, et al. Analysis of single-nucleotide polymorphisms in Japanese rheumatoid arthritis patients shows additional susceptibility markers besides the classic shared epitope susceptibility sequences. Arthritis Rheum 2004;50:63-71. (Pubitemid 38084288)